Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Hypoxia, the cornerstone of glioblastoma

  • Domènech Viñolas, Marta|||0000-0003-4827-9170
  • Hernández, Ainhoa|||0000-0003-4678-6662
  • Plaja, Andrea|||0000-0002-7862-9197
  • Martínez Balibrea, Eva|||0000-0002-4501-7100
  • Balañá, Carmen|||0000-0003-0771-0390
Glioblastoma is the most aggressive form of brain tumor in adults and is characterized by the presence of hypervascularization and necrosis, both caused by a hypoxic microenvironment. In this review, we highlight that hypoxia-induced factor 1 (HIF-1), the main factor activated by hypoxia, is an important driver of tumor progression in GB patients. HIF-1α is a transcription factor regulated by the presence or absence of O2. The expression of HIF-1 has been related to high-grade gliomas and aggressive tumor behavior. HIF-1 promotes tumor progression via the activation of angiogenesis, immunosuppression, and metabolic reprogramming, promoting cell invasion and survival. Moreover, in GB, HIF-1 is not solely modulated by oxygen but also by oncogenic signaling pathways, such as MAPK/ERK, p53, and PI3K/PTEN. Therefore, the inhibition of the hypoxia pathway could represent an important treatment alternative in a disease with very few therapy options. Here, we review the roles of HIF-1 in GB progression and the inhibitors that have been studied thus far, with the aim of shedding light on this devastating disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma

  • Hernández, Ainhoa|||0000-0003-4678-6662
  • Muñoz-Mármol, Ana Maria|||0000-0003-1008-7763
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Alameda, Francesc|||0000-0002-7302-6901
  • Carrato, Cristina|||0000-0002-1953-8287
  • Pineda, Estela|||0000-0003-2128-747X
  • Arpí Lluciá, Oriol|||0000-0002-5578-2092
  • Martinez-García, Maria
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Gut, Marta|||0000-0002-4063-7159
  • Del Barco Berrón, Sonia|||0000-0002-4951-6871
  • Gallego Rubio, Oscar|||0000-0001-5665-0967
  • Dabad, Marc|||0000-0002-6094-747X
  • Mesia, Carlos
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Domènech Viñolas, Marta|||0000-0003-4827-9170
  • Vidal, Noemí|||0000-0002-2852-6667
  • Aldecoa, Iban|||0000-0001-5774-7453
  • de la Iglesia, Nuria|||0000-0002-1083-7715
  • Balañá, Carmen|||0000-0003-0771-0390
RNA-Sequencing (RNA-Seq) can identify gene fusions in tumors, but not all these fusions have functional consequences. Using multiple data bases, we have performed an in silico analysis of fusions detected by RNA-Seq in tumor samples from 139 newly diagnosed glioblastoma patients to identify in-frame fusions with predictable oncogenic potential. Among 61 samples with fusions, there were 103 different fusions, involving 167 different genes, including 20 known oncogenes or tumor suppressor genes (TSGs), 16 associated with cancer but not oncogenes or TSGs, and 32 not associated with cancer but previously shown to be involved in fusions in gliomas. After selecting in-frame fusions able to produce a protein product and running Oncofuse, we identified 30 fusions with predictable oncogenic potential and classified them into four non-overlapping categories: six previously described in cancer; six involving an oncogene or TSG; four predicted by Oncofuse to have oncogenic potential; and 14 other in-frame fusions. Only 24 patients harbored one or more of these 30 fusions, and only two fusions were present in more than one patient: FGFR3::TACC3 and EGFR::SEPTIN14. This in silico study provides a good starting point for the identification of gene fusions with functional consequences in the pathogenesis or treatment of glioblastoma.